2022

1. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

   Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

2. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

   Journal of Clinical Medicine, Vol. 11, Núm. 15